<code id='AB4A062EC7'></code><style id='AB4A062EC7'></style>
    • <acronym id='AB4A062EC7'></acronym>
      <center id='AB4A062EC7'><center id='AB4A062EC7'><tfoot id='AB4A062EC7'></tfoot></center><abbr id='AB4A062EC7'><dir id='AB4A062EC7'><tfoot id='AB4A062EC7'></tfoot><noframes id='AB4A062EC7'>

    • <optgroup id='AB4A062EC7'><strike id='AB4A062EC7'><sup id='AB4A062EC7'></sup></strike><code id='AB4A062EC7'></code></optgroup>
        1. <b id='AB4A062EC7'><label id='AB4A062EC7'><select id='AB4A062EC7'><dt id='AB4A062EC7'><span id='AB4A062EC7'></span></dt></select></label></b><u id='AB4A062EC7'></u>
          <i id='AB4A062EC7'><strike id='AB4A062EC7'><tt id='AB4A062EC7'><pre id='AB4A062EC7'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:696
          Courtesy Sanofi

          LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

          The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.   

          advertisement

          Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          A letter from the executive editor: STAT UnitedHealth investigation
          A letter from the executive editor: STAT UnitedHealth investigation

          MikeReddyforSTATIwanttobringyourattentiontoavitallyimportant investigation STAThaspublishedtoday.For

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          FDA cancer chief on how to get things done: ‘Don’t tell anybody'

          AdobeWASHINGTON—TheFoodandDrugAdministration’stopcancerdrugregulatordoesn’talwaysaskforpermissionbef